U.S., March 5 -- ClinicalTrials.gov registry received information related to the study (NCT07450547) titled 'Phase 2 Study to Assess the Safety and Efficacy of ANG003' on Feb. 09.
Brief Summary: In this study, ANG003, a pancreatic enzyme replacement therapy (PERT; commonly called "enzymes"), is being investigated as a potential treatment for exocrine pancreatic insufficiency (EPI). People with EPI due to Cystic Fibrosis (CF) may be eligible to participate in this study. The primary objective of this study is to evaluate the safety of ANG003 and see if it works as well compared to Creon, an approved PERT.
Study Start Date: April, 2026
Study Type: INTERVENTIONAL
Condition:
Exocrine Pancreatic Insufficiency (EPI)
Cystic Fibrosis (CF)
Int...